PharmAbcine Overview
- Year Founded
-
2008
- Status
-
Acquired/Merged
- Employees
-
40
- Latest Deal Type
-
PIPE
- Financing Rounds
-
20
- Investments
-
1
PharmAbcine General Information
Description
PharmAbcine Inc is a clinical stage biotech company that develops fully human therapeutic monoclonal antibody (mAb) using innovative discovery technology and excellent human resources for the treatment of human diseases, such as cancer and inflammatory diseases.
Contact Information
Website
www.pharmabcine.com(Operating Subsidiary)
Corporate Office
- 2 Floor, Research Building 2, 70
- Yuseong-daero 1689 Beon-Gil, Yuseong-Gu
- Daejeon, 34047
- South Korea
Corporate Office
- 2 Floor, Research Building 2, 70
- Yuseong-daero 1689 Beon-Gil, Yuseong-Gu
- Daejeon, 34047
- South Korea
PharmAbcine Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
PharmAbcine Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
PharmAbcine Patents
PharmAbcine Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025198341-A1 | Antibody trans-binding to tie2 of different cells, and use thereof | Pending | 19-Mar-2024 | ||
| WO-2024181783-A1 | Composition for preventing or treating systemic capillary leak syndrome | Inactive | 28-Feb-2023 | ||
| EP-4464723-A1 | Fusion protein comprising modified anti-vegfr2 (kdr) antibody and use thereof | Pending | 14-Jan-2022 | ||
| EP-4464723-A4 | Fusion protein comprising modified anti-vegfr2 (kdr) antibody and use thereof | Pending | 14-Jan-2022 | ||
| US-20250179192-A1 | Fusion protein comprising modified anti-vegfr2 (kdr) antibody and use thereof | Pending | 14-Jan-2022 | C07K16/2863 |
PharmAbcine Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
PharmAbcine Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
PharmAbcine Acquisitions (1)
PharmAbcine’s most recent deal was a Merger/Acquisition with Good Tire. The deal was made on 01-Oct-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Good Tire | 01-Oct-2024 | Merger/Acquisition | Specialty Retail |
PharmAbcine Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Good Tire | Daejeon, South Korea |
PharmAbcine FAQs
-
When was PharmAbcine founded?
PharmAbcine was founded in 2008.
-
Where is PharmAbcine headquartered?
PharmAbcine is headquartered in Daejeon, South Korea.
-
What is the size of PharmAbcine?
PharmAbcine has 40 total employees.
-
What industry is PharmAbcine in?
PharmAbcine’s primary industry is Drug Discovery.
-
Is PharmAbcine a private or public company?
PharmAbcine is a Private company.
-
What is PharmAbcine’s current revenue?
The current revenue for PharmAbcine is .
-
How much funding has PharmAbcine raised over time?
PharmAbcine has raised $9.9M.
-
Who are PharmAbcine’s investors?
AJU IB Investment, DSC Investment, G.N. Tech Venture Capital, GC Biopharma, and IMM Investment are 5 of 24 investors who have invested in PharmAbcine.
-
When was PharmAbcine acquired?
PharmAbcine was acquired on 28-Jun-2024.
-
Who acquired PharmAbcine?
PharmAbcine was acquired by Tire Bank.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
